Recent news highlights Pro-Dex's Q1 earnings and revenues surpassing prior year levels, contract extensions with major customers, and stock price gains following fiscal year results.

• Pro-Dex reported Q1 earnings and revenues surpassing prior year levels, reflecting strong sales momentum [N1].
• The company’s largest customer extended its supply agreement through calendar 2028, supporting ongoing revenue streams [S1].
• Pro-Dex’s fiscal year 2026 results contributed to an 18% stock price increase and 52-week highs [N5].
• The Helios driver product featuring adaptive torque-limiting software has been released for production, with customer interest noted [N3].
• Pro-Dex announced contract extension with its largest customer in December 2025, reinforcing customer relationships [N6].
• Industry outlooks highlight improving prospects for medical and dental supply stocks including Pro-Dex [N4].

Pro-Dex benefits from strong customer relationships, including a significant contract extension with its largest customer through 2028, supporting backlog and revenue streams. The company’s patented adaptive torque-limiting technology has been well received in key markets such as CMF and thoracic surgery. Recent revenue growth, including a 21% increase in medical device sales and expansion into aerospace and defense machining through APM, demonstrates diversification and operational expansion. Strong liquidity ratios and positive net income for the quarter ended September 30, 2026, reflect financial stability. Continued investment in research and development and new product introductions, such as the Helios driver, support ongoing innovation and potential market penetration.

Pro-Dex faces risks from customer concentration, with one customer accounting for a large majority of sales, which could impact revenue if relationships change. Supply chain challenges, including delays from a proprietary medical grade finish supplier, pose risks to timely product delivery. The company operates in a highly competitive market with larger, better-capitalized competitors and internal manufacturing groups of customers, which may pressure pricing and market share. Regulatory compliance risks exist given the complex FDA and government contracting environment. Variability in order bookings and repair revenues introduces revenue volatility. The company’s expansion into aerospace and defense manufacturing adds operational complexity and regulatory exposure.

Pro-Dex's moat is supported by its proprietary patented adaptive torque-limiting technology and proprietary sealing solutions, which differentiate its surgical drivers and shavers in specialized medical markets. The company’s long-term supply agreements with major customers, including a contract extension through 2028 with its largest customer, provide revenue visibility and customer dependency. Its manufacturing capabilities, including in-house machining and assembly facilities in California, and the acquisition of APM with specialized certifications for aerospace and defense manufacturing, add operational control and diversification. Compliance with FDA and ISO standards and regulatory registrations further support its market position. However, the company operates in a highly competitive environment with larger competitors and faces risks related to supplier dependencies and customer concentration.

• Customer Concentration Risk: One customer accounted for 78% of sales in fiscal 2026, creating dependency that could materially affect revenue if the relationship changes.
• Supply Chain Risk: Delays from key suppliers, including a proprietary medical grade finish supplier, may disrupt production and delivery schedules.
• Competitive Pressure: The company faces intense competition from larger medical device companies and internal manufacturing groups of customers, which may impact pricing and market share.
• Regulatory Compliance Risk: Pro-Dex operates under complex FDA regulations and government contracting requirements; non-compliance could result in penalties or business disruption.
• Revenue Variability: Variability in new order bookings and repair revenues can cause fluctuations in financial performance.

• Pro-Dex, Inc. specializes in design, development, and manufacture of autoclavable, battery-powered and electric multi-function surgical drivers and shavers primarily for orthopedic, thoracic, and craniomaxillofacial (CMF) markets.
• The company holds patented adaptive torque-limiting technology and proprietary sealing solutions.
• Primary customers are medical device distributors; top three customers accounted for 92% of sales in fiscal 2026.
• Pro-Dex also provides engineering, quality, and regulatory consulting services.
• The company manufactures and sells rotary air motors to various industries, but this is a de minimis portion of business.
• In fiscal 2026, Pro-Dex acquired Advanced Precision Machining, LLC (APM), which manufactures precision machined parts and assemblies for aerospace and defense industries and serves as a Prime Contractor for the U.S. Government.
• APM operates a manufacturing facility in Costa Mesa, California, with ITAR and JCP certifications.
• Pro-Dex's medical device products are manufactured in Irvine, California and assembled in Tustin, California.
• The company owns a 25,000 square foot industrial building in Tustin, California (Franklin Property) acquired in 2020 for growth capacity.
• Fiscal 2026 revenue was $20.56 million for the quarter ended September 30, 2026, with net income of $3.05 million and basic EPS of $0.95.
• Revenue increased 11% year-over-year for the quarter ended September 30, 2026.
• Medical device sales accounted for 85% of net sales in Q1 2027, with orthopedic sales up 16%, CMF sales up 39%, and thoracic sales up 30% compared to prior year quarter.
• Industrial and scientific sales increased 330% due to APM acquisition.
• Repair revenue decreased 44% due to fewer repairs of legacy orthopedic handpieces.
• Gross margin improved to 33% from 29% year-over-year for the quarter ended September 30, 2026.
• Backlog was approximately $43.1 million as of September 30, 2026, with $42.4 million scheduled for delivery during fiscal 2027.
• The largest customer extended supply agreement through calendar 2028.
• Pro-Dex's Helios driver product for CMF applications featuring adaptive torque-limiting software has been released for production.
• The company faces competition from larger medical device companies and internal manufacturing groups of customers.
• Pro-Dex complies with FDA regulations, holds FDA Establishment Registration, California Device Manufacturing License, and ISO certifications for its facilities.
• Research and development expenses were $1.21 million for the quarter ended September 30, 2026.
• Liquidity ratios as of September 30, 2026: current ratio 4.19, cash ratio 1.01, cash and equivalents $11.76 million, short-term investments $1.23 million, current assets $53.95 million, current liabilities $12.88 million.
• The company emphasizes employee retention with competitive compensation, benefits, and equity programs; had 206 employees as of June 30, 2026.
• Risks include supply chain delays (notably a proprietary medical grade finish supplier), competition, regulatory compliance, and variability in order bookings.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.